Urinary Cannabinoid Detection Times After Controlled Oral Administration of [[Delta].Sup.9]-Tetrahydrocannabinol to Humans (Drug Monitoring and Toxicology) (Clinical Report) Urinary Cannabinoid Detection Times After Controlled Oral Administration of [[Delta].Sup.9]-Tetrahydrocannabinol to Humans (Drug Monitoring and Toxicology) (Clinical Report)

Urinary Cannabinoid Detection Times After Controlled Oral Administration of [[Delta].Sup.9]-Tetrahydrocannabinol to Humans (Drug Monitoring and Toxicology) (Clinical Report‪)‬

Clinical Chemistry 2003, July, 49, 7

    • €2.99
    • €2.99

Publisher Description

[[Delta].sup.9]-Tetrahydrocannabinol (THC)6 is the major psychoactive cannabinoid in the marijuana plant Cannabis sativa. Clinical marijuana smoking studies have characterized the urinary pharmacokinetics of THC after inhalation (1-6); ingestion of cannabis has been investigated to a lesser extent (7-11). Since the mid-1990s, food products derived from cannabis plants and advertised as nutritional supplements have been available in the US; one such item is hemp seed oil. Manufacturers suggest that hemp oil is of value as a nutritional supplement because of its high concentration of the essential fatty acids [omega]-linolenic and linoleic acid. Although the hemp seed kernel does not have a substantial THC concentration, hemp oils have been found to contain a wide range of THC concentrations (12-14). The THC content of hemp oil is dependent on the effectiveness of seed cleaning and drying procedures and oil filtration processes. THC contamination originates from plant resin covering the surrounding seed hull. Ingestion of these products may produce positive urine drug tests (13, 15). This has led to questions about the validity of urine drug tests intended to deter drug use in treatment, workplace, criminal justice, and military programs. Several studies have reported that ingestion of hemp oil causes positive urine tests for cannabinoids (12, 16-18). Lehmann et al. (12) reported THC concentrations of 3-1500 [micro]g/g in 25 hemp oil samples. Six individuals ingested one or two tablespoons of hemp oil containing 1500 [micro]g/g THC (11 and 22 g of hemp oil, or ~16.5-33 mg THC). Positive urine specimens were observed with a 50 [micro]g/L cannabinoid immunoassay cutoff and a 15 [micro]g/L 11-nor-9-carboxy-[[Delta].sup.9]-tetrahydrocannabinol (THCCOOH) gas chromatography-mass spectrometry (GC/MS) cutoff for up to 6 days. Costantino et al. (18) reported that seven individuals ingesting 15 mL of hemp oil of an unknown THC concentration had positive urine drug tests by immunoassay at a cutoff of 20 [micro]g/L for up to 48 h after ingestion. GC/MS analysis of urine specimens for THCCOOH, the primary urinary metabolite of THC, identified concentrations up to 78.6 [micro]g/L. This is substantially above the federally mandated urine THCCOOH confirmation cutoff concentration of 15 [micro]g/L. It is of concern that legitimate consumption of hemp oil may be interpreted as illicit drug exposure and that hemp oil ingestion may be used to conceal illicit cannabis use.

GENRE
Science & Nature
RELEASED
2003
1 July
LANGUAGE
EN
English
LENGTH
38
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
PROVIDER INFO
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
234.9
KB
Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring
2012
Automated Liquid-Chromatographic Analyzer Used for Toxicology Screening in a General Hospital: 12 Months' Experience (Drug Monitoring and Toxicology) Automated Liquid-Chromatographic Analyzer Used for Toxicology Screening in a General Hospital: 12 Months' Experience (Drug Monitoring and Toxicology)
1997
Drug Disposition and Pharmacokinetics Drug Disposition and Pharmacokinetics
2011
Standards of Laboratory Practice: Analgesic Drug Monitoring (Nacb Symposium) Standards of Laboratory Practice: Analgesic Drug Monitoring (Nacb Symposium)
1998
Pharmacokinetics of Pyrazinamide in Children with Primary Progressive Disease of Lungs. Pharmacokinetics of Pyrazinamide in Children with Primary Progressive Disease of Lungs.
2008
[[Alpha].Sub.1]-Microglobulin Is Stable in Human Urine Ex Vivo (Letters) (Letter to the Editor) [[Alpha].Sub.1]-Microglobulin Is Stable in Human Urine Ex Vivo (Letters) (Letter to the Editor)
2002
Impact of the Third Cholesterol Report from the Adult Treatment Panel of the National Cholesterol Education Program on the Clinical Laboratory (Special Report) Impact of the Third Cholesterol Report from the Adult Treatment Panel of the National Cholesterol Education Program on the Clinical Laboratory (Special Report)
2002
DNA Methylation Changes in Sera of Women in Early Pregnancy are Similar to Those in Advanced Breast Cancer Patients (Technical Briefs) DNA Methylation Changes in Sera of Women in Early Pregnancy are Similar to Those in Advanced Breast Cancer Patients (Technical Briefs)
2004
Colorectal Carcinoma Susceptibility and Metastases are Associated with Matrix Metalloproteinase-7 Promoter Polymorphisms (Technical Briefs) Colorectal Carcinoma Susceptibility and Metastases are Associated with Matrix Metalloproteinase-7 Promoter Polymorphisms (Technical Briefs)
2003
High-Sensitivity C-Reactive Protein As a Predictor of All-Cause Mortality: Implications for Research and Patient Care (Editorial) High-Sensitivity C-Reactive Protein As a Predictor of All-Cause Mortality: Implications for Research and Patient Care (Editorial)
2008
Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer (Technical Briefs) Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer (Technical Briefs)
2005
Hemoglobin Variants and Hemoglobin [a.Sub.1C] Analysis: Problem Solved?(Editorial) Hemoglobin Variants and Hemoglobin [a.Sub.1C] Analysis: Problem Solved?(Editorial)
2003